# Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

> **NCT03672188** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 82 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** VIR-2218
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03672188
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-14
- **Primary completion:** 2020-09-03
- **Final completion:** 2020-09-03
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2021-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672188, "Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03672188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*